SCHEMBL2374833

SCHEMBL2374833

O=C(NCc1cccc(C(F)(F)F)c1)c1csc(Nc2ccncn2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 5/20 0.52
DHFR P00374 1/20 0.49
MAPK1 P28482 2/20 0.46
IDE P14735 1/20 0.46
MAPK10 P53779 1/20 0.46
HRH4 Q9H3N8 1/20 0.46
MLYCD O95822 1/20 0.45
ATG4B Q9Y4P1 2/20 0.44
MEN1 O00255 1/20 0.44
PLA2G1B P04054 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TRPV1 Q8NER1 1/20 0.44
MMP13 P45452 1/20 0.44
DDT P30046 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16501138 0.89 DHFR (0.50) DHFRHRH4MLYCDATG4BMEN1
SCHEMBL669856 0.85 MMP13 (0.48) MPLMAPK1GAAMMP13LMNA
SCHEMBL29072859 0.85 MMP13 (0.48) MPLMAPK1GAAMMP13LMNA
SCHEMBL2373426 0.83 ROCK1 (0.54) CYP3A4CYP2D6KMT2AMMP13HPGD
SCHEMBL31681838 0.83 ROCK1 (0.54) CYP3A4CYP2D6KMT2AMMP13HPGD
SCHEMBL31681851 0.82 HTT (0.55) MEN1KMT2AMMP13LMNAALDH1A1
SCHEMBL2373894 0.82 HTT (0.55) MEN1KMT2AMMP13LMNAALDH1A1
SCHEMBL27913945 0.81 MEN1 (0.59) DHFRHRH4MLYCDATG4BMEN1
SCHEMBL24139180 0.79 SMN1; SMN2 (0.53) MPLMAPK1MEN1CYP1A2CYP3A4
SCHEMBL2374577 0.79 MPL (0.46) MPLMAPK1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410397-B2 Methods of enhancing cell survival of stem cells THE SCRIPPS RESEARCH INSTITUTE (US) 2025-09-09 US disclosed
EP-4585589-A2 STEM CELL CULTURES The Scripps Research Institute (US) 2025-07-16 EP disclosed
EP-4296270-B1 A COMPOSITION COMPRISING STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2025-06-18 EP disclosed
EP-4296270-A2 A COMPOSITION COMPRISING STEM CELL CULTURES The Scripps Research Institute (US) 2023-12-27 EP disclosed
EP-3936508-B1 A COMPOSITION COMPRISING STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2023-12-06 EP disclosed
EP-3936508-A1 A COMPOSITION COMPRISING STEM CELL CULTURES The Scripps Research Institute (US) 2022-01-12 EP disclosed
US-20210403862-A1 METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS THE SCRIPPS RESEARCH INSTITUTE 2021-12-30 US disclosed
US-20210403862-A1 METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS THE SCRIPPS RESEARCH INSTITUTE 2021-12-30 US disclosed
EP-3623374-B1 STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2021-09-08 EP disclosed
EP-3623374-B1 STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2021-09-08 EP disclosed
EP-2370445-B1 STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2014-07-23 EP disclosed
EP-2370445-B1 STEM CELL CULTURES SCRIPPS RESEARCH INST (US) 2014-07-23 EP disclosed
US-20110294761-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2011-12-01 US disclosed
US-8044201-B2 Stem cell cultures THE SCRIPPS RESEARCH INSTITUTE (US) 2011-10-25 US disclosed
US-8044201-B2 Stem cell cultures THE SCRIPPS RESEARCH INSTITUTE (US) 2011-10-25 US disclosed
US-8044201-B2 Stem cell cultures THE SCRIPPS RESEARCH INSTITUTE (US) 2011-10-25 US disclosed
US-20110224233-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2011-09-15 US disclosed
US-20110224233-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2011-09-15 US disclosed
US-20110224233-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2011-09-15 US disclosed
WO-2010065721-A1 STEM CELL CULTURES THE SCRIPPS RESEARCH INSTITUTE (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294761-A1 STEM CELL CULTURES NES, CD44, MCL1 MPL 819/4885DHFR 2743/4885MAPK1 3418/4885
US-12410397-B2 Methods of enhancing cell survival of stem cells MCL1, BCL2, BCLAF1 MPL 1128/4885DHFR 1545/4885MAPK1 3981/4885
US-20210403862-A1 METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS MCL1, BCL2, BCLAF1 MPL 1128/4885DHFR 1545/4885MAPK1 3981/4885
US-20110224233-A1 STEM CELL CULTURES NES, CD44, MCL1 MPL 819/4885DHFR 2743/4885MAPK1 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.